Abstract Colonic drug delivery can facilitate access to unique therapeutic targets and has the potential to enhance drug bioavailability whilst reducing off-target effects. Delivering drugs to the colon requires considered formulation…

Abstract Enteral administration is the most convenient route despite the gastrointestinal physiological barriers. Nanostructured lipid carriers (NLCs) have emerged as a promising strategy for improving therapeutic compound oral…

The present Special Issue on Drug Delivery and Translational Research in Europe brings together representative examples of the work being carried out in pharmaceutical laboratories, both within universities or research institutions, and in…

CRISPR-Cas9 has emerged as a powerful technology that relies on Cas9/sgRNA ribonucleoprotein complexes (RNPs) to target and edit DNA. However, many therapeutic targets cannot currently be accessed due to the lack of carriers that can…

Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older. Epidiolex was previously…

6-Shogaol is one component of ginger, which has been described to possess various health-promoting effects including anticancer, anti-inflammatory, antioxidant and antiatherogenic. However, poor water solubility has limited the…

Silymarin, a mixture of flavonolignan and flavonoid polyphenolic compounds extractable from milk thistle (Silybum marianum) seeds, is gaining an increasingly widespread clinical consensus as a natural remedy in the treatment of numerous…

Canada has a long and rich history of ground-breaking research in drug delivery within academic institutions, pharmaceutical industry and the biotechnology community. Drug delivery refers to approaches, formulations, technologies, and…

The development of cannabinoids in the pharmaceutical industry has exploded over the past few years. With the gradual liberation of regulations worldwide that govern cannabis and its pharmaceutical derivatives for medicinal use, this week…

Huperzine A (HupA) is a selective acetylcholinesterase inhibitor used to treat Alzheimer’s disease. The existing dosage of HupA lacks brain selectivity and can cause serious side effects in the gastrointestinal and peripheral cholinergic…